Prothena Corporation plc (PRTA) - Total Liabilities
Based on the latest financial reports, Prothena Corporation plc (PRTA) has total liabilities worth $57.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PRTA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Prothena Corporation plc - Total Liabilities Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's total liabilities have evolved over time, based on quarterly financial data. See PRTA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Prothena Corporation plc Competitors by Total Liabilities
The table below lists competitors of Prothena Corporation plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aris Water Solutions Inc
NYSE:ARIS
|
USA | $689.21 Million |
|
Enjoyor
SHE:300020
|
China | CN¥2.42 Billion |
|
Wall Financial Corporation
TO:WFC
|
Canada | CA$712.20 Million |
|
Magnera Corp placeholder
NYSE:MAGN
|
USA | $2.86 Billion |
|
Aerostar Bacau
RO:ARS
|
Romania | RON188.66 Million |
|
Gallant Precision Machining Co Ltd
TWO:5443
|
Taiwan | NT$6.89 Billion |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
USA | $44.84 Million |
|
Weave Communications Inc
NYSE:WEAV
|
USA | $127.85 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Prothena Corporation plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PRTA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prothena Corporation plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prothena Corporation plc (2010–2024)
The table below shows the annual total liabilities of Prothena Corporation plc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $60.18 Million | -55.43% |
| 2023-12-31 | $135.02 Million | -0.72% |
| 2022-12-31 | $135.99 Million | -5.11% |
| 2021-12-31 | $143.32 Million | -3.79% |
| 2020-12-31 | $148.97 Million | +1.79% |
| 2019-12-31 | $146.35 Million | -16.75% |
| 2018-12-31 | $175.80 Million | +97.22% |
| 2017-12-31 | $89.14 Million | -5.74% |
| 2016-12-31 | $94.57 Million | +284.96% |
| 2015-12-31 | $24.57 Million | +72.68% |
| 2014-12-31 | $14.23 Million | +55.66% |
| 2013-12-31 | $9.14 Million | +226.55% |
| 2012-12-31 | $2.80 Million | -72.16% |
| 2011-12-31 | $10.05 Million | +214.19% |
| 2010-12-31 | $3.20 Million | -- |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more